Skip to main content

Table 1 Patient characteristics

From: Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway

 

Total (N = 69)

Age (yr)

57 ± 1

Female (%)

11 (16)

Body mass index (kg/m2)

23.7 ± 0.4

ASA physical status (%)

 

 I

21 (30)

 II

48 (70)

Mechanical ventilation duration (hr)

4.5 [3.0, 6.5]

Surgery type (%)

 

 Spine surgery

48 (70)

 Brain surgery

11 (16)

 Gastrointestinal surgery

10 (14)

Baseline FGF21 (pg/ml)

152.9 ± 7.9

Postoperative FGF21 (pg/ml)

190.6 ± 10.2

  1. Categorical variables are presented as N (%), continuous variables are presented as mean ± SEM or median [quartile 1, quartile 3]. ASA, American Society of Anesthesiologists; FGF21, fibroblast growth factor 21
Back to article page

Critical Care

ISSN: 1364-8535